L-Boronophenylalanine intravenous administration
Phase 1Small molecule
L-Boronophenylalanine intravenous administration is one of 27 small molecule programs targeting Head and Neck Carcinoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Head and Neck Carcinoma
#DrugCompanyPhaseTrials
1IC-Green
CCHX Technologies Inc.
Approved
Opdivo
Bristol-Myers SquibbPhase 3
Trexall
Alnylam PharmaceuticalsPhase 3
Javlor
Bristol-Myers SquibbPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Taxotere
AAvyxa
Phase 3
Vectibix
AmgenPhase 2
Iressa
AstraZenecaPhase 2
Taxol
TevaPhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- NNeutron Therapeutics, LLC